Ibraiz Iqbal, MD
Interventional Cardiology · Somerset, KYNPI 1720067168
Payments from drug & device makers
Across 233 payments — averaging $34.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Merck$625
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$564
- Novartis$546
- AstraZeneca$324
- Johnson & Johnson$181
- plus $1K from 21 others
What the payments were for
- Travel & lodging$2,90136%
- Food & beverage$4,98563%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $4,633 |
| Merck | 37 | $625 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 44 | $564 |
| Novartis | 30 | $546 |
| AstraZeneca | 19 | $324 |
| Johnson & Johnson | 8 | $181 |
| Amarin Pharma, Inc. | 10 | $149 |
| Baxter Healthcare | 3 | $111 |
| Pfizer | 7 | $108 |
| Lundbeck LLC | 5 | $104 |
| Amgen | 5 | $89 |
| Sanofi-aventis U.S. LLC | 6 | $87 |
| Boston Scientific | 5 | $84 |
| Kestra Medical Technology Services, Inc. | 2 | $44 |
| Thrombolex, Inc. | 2 | $43 |
| Biotronik Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $28 |
| Tempus AI, Inc | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Acist Medical Systems, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| GSK | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$2,272
- PERCLOSE PROGLIDE$1,531
How this compares
$7,951 in reported general payments places this provider in the 40th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 445 | $439,456 |
| EntrestoSacubitril/Valsartan | 182 | $205,184 |
| FarxigaDapagliflozin Propanediol | 120 | $95,624 |
| BrilintaTicagrelor | 156 | $92,950 |
| JardianceEmpagliflozin | 68 | $59,075 |
| VerquvoVericiguat | 40 | $41,342 |
| XareltoRivaroxaban | 46 | $39,545 |
| Ranolazine ErRanolazine | 336 | $21,807 |
| InpefaSotagliflozin | 15 | $13,406 |
| Prasugrel Hcl | 87 | $9,206 |
| Midodrine Hcl | 121 | $8,079 |
| Repatha SureclickEvolocumab | 12 | $7,804 |
| Metoprolol Succinate | 688 | $6,033 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 573 | $4,084 |
| Losartan Potassium | 719 | $3,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $108 | $439,456445 claims |
| NovartisEntresto | $546 | $205,184182 claims |
| AstraZenecaFarxiga, Brilinta | $324 | $188,574276 claims |
| Boehringer IngelheimJardiance | $38 | $59,07568 claims |
| MerckVerquvo | $625 | $41,34240 claims |
| Johnson & JohnsonXarelto | $181 | $39,54546 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $28 | $13,40615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Somerset
- Thomas TuLouisville$1.4M
- Amit SrivastavaEdgewood$736K
- Avichai EresLexington$616K
- Naresh SolankhiLouisville$545K
- Sreedevi GondiLouisville$535K
- Steve LinLexington$372K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$256K
- James FordPaducah$227K
- Ganesh Keshav ThirunavukkarasuLexington$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.